Skip to content
10-K

Annual Report

Syndax Pharmaceuticals, Inc. SNDX

0000950170-25-030394

← back to feed
Filed
Mar 3, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 24, 2025 86.02M sh
Short Term Debt FY 2024 · Dec 31, 2023 $0
Short Term Investments FY 2024 · Dec 31, 2023 $275.3M
Current Liabilities FY 2024 · Dec 31, 2023 $58.1M
Total Liabilities FY 2024 · Dec 31, 2023 $58.68M
Current Assets FY 2024 · Dec 31, 2023 $580.88M
Total Assets FY 2024 · Dec 31, 2023 $612.88M
Shares Diluted FY 2024 · Dec 31, 2022 60.76M sh
Operating Cash Flow FY 2024 · Dec 31, 2022 −$133.68M
Cash And Equivalents FY 2024 · Dec 31, 2022 $74.36M
Eps Diluted FY 2024 · Dec 31, 2022 −$2.46
Eps Basic FY 2024 · Dec 31, 2022 −$2.46
Sga Expense FY 2024 · Dec 31, 2022 $33.26M
Rd Expense FY 2024 · Dec 31, 2022 $118.5M
Net Income FY 2024 · Dec 31, 2022 −$149.34M
Operating Income FY 2024 · Dec 31, 2022 −$151.76M
Revenue FY 2024 · Dec 31, 2022 $0
Stockholders Equity FY 2024 · Dec 31, 2021 $408.37M